| Budget Amount *help |
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 2000: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1999: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1998: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Research Abstract |
The cases of chronic renal failure have recently grown in small animal clinics like human patients. The methodological studies of diagnosis and therapy have been thus conducted but no detailed description of renal hypertension has been presented. Therefore, we report herein the possible contribution of renal disorders to the pathogenesis of renal hypertension in cat models of chronic renal failure using a telemetry system that allows monitoring the blood pressure in awake unrestrained animals for 24 consecutive hours, focusing on the blood pressure and certain parameters in the renin-angiotensin-alsosterone system. Moreover, we will describe the effect of an angiotensin converting enzyme inhibitor on renal hypertension in the present animal models of chronic renal failure. [Results] The evaluation of renal function in the 5 cats demonstrated significantly elevated BUN and serum Cr levels (p<0.05) and lowered CCr (p<0.05) after the operation for chronic renal failure when compared with
… More
the preoperative values. In addition, the systolic, mean and diastolic pressures after the operation were all significantly higher than the control values (p<0.05). Plasma renin activity, angiotensin I (ANG-I), angiotensin II (ANG-II) and ALD were all significantly elevated after the operation when compared with the preoperative values (p<0.05). In the animal models of chronic renal failure, benazepryl hydrochloride produced a significant fall in systolic, mean and diastolic pressures during the treatment period when compared with the pre-treatment levels (p<0.05). The pressures returned to almost the same as the pre-treatment levels after the discontinuation of the drug. At the same time, the ACE-I led to the significant decreases in plasma angiotensin II and ALD during the treatment period (p<0.05), followed by the sustained low levels after the discontinuation of the drug. On the other hand, the ACE-I did not alter either plasma renin activity or angiotensin I (ANG-I) level during the observation period. The indices of renal function (BUN, Cr, CCr) showed no significant change before, during and after the treatment with the ACE-I.In this study, the animal models of chronic renal failure demonstrated renal hypertension, which was obviously reversed by the ACE-I without advancing the renal disorder. It has been therefore suggested that the management of high blood pressure, which is one of the factors aggravating the condition of chronic renal failure, could stop the progression of chronic renal failure and ACE-I's are of great benefit to small animal patients with hypertension in future. Less
|
